Fate Therapeutics (FATE) Free Cash Flow (2012 - 2026)

Fate Therapeutics has reported Free Cash Flow for 15 years, with the latest figure at -$30.8 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 10.52% year-over-year to -$30.8 million; the trailing twelve-month figure through Mar 2026 stood at -$102.5 million (up 17.45% YoY), and the FY2025 full-year result was -$106.1 million, up 13.76% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$30.8 million, down from -$18.6 million in the prior quarter.
• The five-year high for Free Cash Flow was -$18.6 million in Q4 2025, with the low at -$74.5 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$37.7 million across 5 years, with a median of -$32.1 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 118.78% — and 2023, when it soared 58.81%.
• Fate Therapeutics' Free Cash Flow stood at -$74.5 million in 2022, then soared by 58.81% to -$30.7 million in 2023, then rose by 8.94% to -$27.9 million in 2024, then soared by 33.56% to -$18.6 million in 2025, then sank by 66.21% to -$30.8 million in 2026.
• The last three Free Cash Flow figures came in at -$30.8 million (Q1 2026), -$18.6 million (Q4 2025), and -$26.6 million (Q3 2025), per Business Quant data.